Promoted Content Promoted Content


Find Drugs for Otolaryngology (Ear, Nose, Throat) in Phase II Clinical Development in UNITED STATES


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mometasone Furoate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: LYR-210

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: LianBio

            Deal Size: $147.0 million Upfront Cash: $12.0 million

            Deal Type: Partnership June 02, 2021


            LYR-210 is an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis (CRS), a debilitating inflammatory disease of the nasal passages.